Oregon Health And Science University

The availability of more effective and less toxic anticancer agents has made it increasingly difficult for clinicians to discern when to discontinue treatment for patients with advanced solid tumors.

Combining radiotherapy and pembrolizumab appeared safe and induced promising responses among patients with advanced non-small cell lung cancer, according to results of two separate phase 2 studies published in JAMA Oncology.

Pharmacists, front office staff and physicians worked together to boost the number of naloxone prescriptions at a clinic in rural Oregon, according to a report in Annals of Family Medicine.

CHICAGO — BLU-667 demonstrated durable and potent antitumor activity among patients with RET-altered advanced medullary thyroid cancer or RET-fusion positive papillary thyroid cancer, according to results of the ARROW study presented at ASCO Annual Meeting.

An increase in the number of immune checkpoint inhibitors approved by the FDA, along with more indications, means that 43% of patients with cancer in the United States are eligible to receive these drugs, according to an analysis published in JAMA Network Open.

PHILADELPHIA — When factoring in all the costs associated with chimeric antigen receptor T-cell therapy, hospitals may charge as much as $1.5 million or more to avoid losing money, according to Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University’s Knight Cancer Institute.

Individuals previously diagnosed with a hematologic malignancy appeared at higher risk for developing head and neck cancers, according to results of a retrospective study published in JAMA Otolaryngology – Head & Neck Surgery.

Genetic testing can help increase early detection of melanoma among patients and their family members, according to a presenter at HemOnc Today New York.

Despite treatment advances and corresponding improvements in survival, suicide rates among those with cancer are alarmingly high — two times that of the general U.S. population.

SAN DIEGO — Chimeric antigen receptor T-cell therapy with tisagenlecleucel induced durable responses among heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma, according to 19-month follow-up results from the phase 2 JULIET trial presented at ASH Annual Meeting and Exposition.